LifeMD price target raised to $10 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on LifeMD (LFMD) to $10 from $9 and keeps a Buy rating on the shares. The company reported a Q4 beat and its 2026 revenue is expected to grow 13%-19%, the analyst tells investors in a research note.

Claim 70% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential